XYZAL ALLERGY 24HR

Peak

levocetirizine dihydrochloride

Sanofi
NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2

Clinical Trials (2)

NCT00628108Phase 3Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Started Mar 2008
69 enrolled
Allergic RhinitisChronic Urticaria
NCT00619801Phase 3Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

Started Mar 2008
173 enrolled
Allergic RhinitisChronic Urticaria
Company
Sanofi
Sanofi
PARIS, France
1139 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers